TICKERNERD
Menu
RMDHealthcare · Medical Instruments & Supplies

RMD Stock Forecast: ResMed, Inc. Price Predictions for 2026-2027

Last close, 5 Oct 2026
$223
+1.81% on the day

The 20 Wall Street analysts covering ResMed, Inc. hold a median 12-month price target of $235 — +5.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 72 of 100 as at 3 Oct 2026 — in the upper half. Here, the model and the Street point the same way.

Market cap
$31.6B
Ticker Nerd rank
72 / 100
Median analyst target
$235
Analysts covering
20
Revenue$1.5B+8.6% y/y
Operating income$448.7M
Net income$383.4M
Free cash flow$397.4M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+0.3%
1M
−2.4%
YTD
−6.7%
1Y
−19.2%
From 52W high
−20.5%
From 52W low
+22.3%
$182
$280
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

RMD stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores ResMed, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 3 Oct 2026
72 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
96
Volatility
96
Value
88
Issuance
84
Growth
61
Revisions
54
Accruals
43
Momentum
35
Size
7

Quality (96): The business earns solid, repeatable profits on what it owns.

Momentum (35): The shares have been drifting down relative to others.

Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

RMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$200$250$300Jan 26Apr 26Jul 26Oct 26RMDHigh $320Median $235Low $175

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says20 analysts
9 Buy10 Hold1 Sell
Low $175Median $235High $320

The green dot is the last close — the median target sits +5.4% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 3 moved their price target up and 7 moved it down.

DateFirmActionRatingTarget
15 Sept 2026RBC CapitalUpgradeOutperform$244 → $262
31 Aug 2026KeybancMaintainsOverweight—
31 Aug 2026KeybancMaintainsOverweight$255 → $267
19 Aug 2026Rothschild & CoInitiatesNeutral$230
19 Aug 2026Rothschild & CoInitiatesNeutral—
7 Aug 2026KeybancMaintainsOverweight—
7 Aug 2026KeybancMaintainsOverweight$260 → $255
7 Aug 2026Piper SandlerMaintainsNeutral$233 → $225
7 Aug 2026Piper SandlerMaintainsNeutral—
7 Aug 2026RBC CapitalMaintainsSector Perform$234 → $244
7 Aug 2026RBC CapitalMaintainsSector Perform—
7 Aug 2026Wells FargoMaintainsEqual-Weight$225 → $215
7 Aug 2026Wells FargoMaintainsEqual-Weight—
15 July 2026MizuhoMaintainsOutperform$235 → $220
15 July 2026MizuhoMaintainsOutperform—
13 July 2026CitigroupDowngradeNeutral$270 → $235
13 July 2026CitigroupDowngradeNeutral—
10 July 2026JefferiesMaintainsHold$240 → $225
10 July 2026JefferiesMaintainsHold—
8 July 2026RBC CapitalMaintainsOutperform$321 → $276

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. RMD appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

RMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 5 Oct 2026, ResMed, Inc. returned −19.2% against +16.2% for the S&P 500, dividends included.

RMD vs S&P 500, last 12 monthsTotal return, rebased to 100
60708090100110120Jan 26Apr 26Jul 26Oct 26RMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.2%
Analysts raising
11
Analysts cutting
3
Fundamentals

ResMed, Inc. (RMD) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
21.0×

Cheaper than 35% of US stocks

Price / sales
5.4×

Cheaper than 23% of US stocks

Price / book
4.8×

Cheaper than 21% of US stocks

EV / EBITDA
14.8×

Cheaper than 23% of US stocks

Growth & margins
Revenue growth (YoY)
8.6%

Higher than 48% of US stocks

Earnings growth (YoY)
1.0%

Higher than 37% of US stocks

Gross margin
58.8%

Higher than 72% of US stocks

Operating margin
30.9%

Higher than 88% of US stocks

Net margin
26.9%

Higher than 87% of US stocks

Returns & dividend
Return on equity
24.3%

Higher than 85% of US stocks

Return on assets
14.0%

Higher than 96% of US stocks

Dividend yield
1.2%

Higher than 55% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

ResMed, Inc. (RMD) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • ResMed, Inc. has a market value of $31.6B and an enterprise value of $30.9B.

  • Revenue in the twelve months to 30 June 2026: $5.7B. The latest quarter grew 8.6% year on year.

  • Net income over the same four quarters: $1.5B, a 26.9% net margin.

  • Diluted earnings per share, trailing twelve months: $10.43.

  • Free cash flow in the twelve months to 30 June 2026: $1.6B.

  • ResMed, Inc. spent $700.0M on share buybacks and $349.7M on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 144.2M.

  • Trailing P/E: 21.0×; forward P/E: 16.5× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 1.21%, paying out 23% of earnings.

  • ResMed, Inc. employs 11,370 people — $497K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 5 Oct 2026

Data provided by Twelve Data

Peers

RMD vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelMedical Instruments & Supplies
CompanyMarket capTKN rank
RMDResMed, Inc.$31.6B
72
ALCAlcon AG$31.8B
68
WSTWest Pharmaceutical Services, Inc.$26.3B
94
MDLNMedline, Inc.$46.8B
19
BDXBecton, Dickinson & Co.$48.7B
93
SOLVSolventum Corp.$15.2B
92
BAXBaxter International, Inc.$12.1B
90

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own ResMed, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest RMD news & analysis

Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026

GlobeNewsWire · 1 Oct 2026neutral

ResMed announced it will release its financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. The company will also host a webcast following the release to discuss the results, during which additional forward-looking information may be presented.

Why it matters — This sets the scheduled date for ResMed's quarterly earnings report, which is the next key event investors will watch for updates on the company's performance.

ResMed Targets 12%-14% EPS Growth as GLP-1 Patients Lift Sleep Therapy Demand

MarketBeat · 21 Sept 2026positive

ResMed outlined its growth outlook, margin strategy and portfolio plans during a Morgan Stanley discussion, emphasizing demand generation, patient adherence and ongoing product innovation in sleep and respiratory care. Executives highlighted a 12%-14% EPS growth target, with GLP-1 patients lifting sleep therapy demand.

Why it matters — A ResMed watcher would care because the company's stated growth outlook and focus on patient adherence and innovation signal how it plans to sustain momentum in sleep and respiratory care amid rising demand from GLP-1 patients.

Sleep Device Maker ResMed Gets an Upgrade. Analysts See a Lot to Like.

Barrons · 15 Sept 2026positive

Barrons reports that analysts have upgraded ResMed, a sleep device maker, citing competitive setbacks elsewhere as positioning the company to gain additional market share. The upgrade reflects favorable conditions for ResMed in its market.

Why it matters — The upgrade and analyst optimism suggest that ResMed may be well placed to benefit from competitors' difficulties, which could matter for those tracking its market position.

ResMed Inc. (RMD) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Seeking Alpha · 15 Sept 2026neutral

ResMed Inc. (RMD) presented at the Morgan Stanley 24th Annual Global Healthcare Conference, with a transcript of the presentation published by Seeking Alpha. The item records the company's participation in the conference.

Why it matters — A ResMed watcher would care because conference presentations typically offer insight into the company's strategy and outlook for investors and analysts.

Is This the Right Time to Retain Resmed Stock in Your Portfolio?

Zacks Investment Research · 15 Sept 2026neutral

Zacks Investment Research published an analysis weighing whether it is the right time to retain ResMed (RMD) stock in an investor's portfolio. The piece notes that RMD's software portfolio optimization, mask innovation, and solid financial health support growth, while macroeconomic pressures and competition pose risks.

Why it matters — RMD watchers would care because the analysis highlights the key growth drivers and headwinds that could influence the company's outlook.

FAQ

Frequently asked questions about RMD stock

What is the RMD stock price forecast for 2026-2027?

The 20 Wall Street analysts covering ResMed, Inc. have a median 12-month price target of $235, with estimates ranging from $175 to $320. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RMD stock a buy right now?

Of the 20 analysts covering ResMed, Inc., 9 rate it a Buy, 10 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks ResMed, Inc. 72 out of 100 across roughly 4,600 US stocks as at 3 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RMD?

As at 3 Oct 2026, ResMed, Inc. ranks 72 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (96 of 100).

Will RMD stock go up?

No one can know that. What the data says: the median 12-month target from 20 analysts implies +5.4% from the last close, and Ticker Nerd's factor model ranks ResMed, Inc. 72 out of 100 as at 3 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RMD stock forecast for 2030?

No analyst covering ResMed, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $175 to $320 over the next 12 months.

How has RMD stock performed over the past year?

ResMed, Inc. returned -19.2% over the 12 months to 5 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does ResMed, Inc. do?

ResMed Inc. is a global medical technology and digital health company focused on sleep health, respiratory care, and out-of-hospital care.

What is the latest news on RMD?

The most recent item we track (GlobeNewsWire, 1 Oct 2026): "Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026". ResMed announced it will release its financial and operational results for the first quarter of fiscal year 2027 on Thursday, October 29, 2026, after the New York Stock Exchange closes. The company will also host a webcast following the release to discuss the results, during which additional forward-looking information may be presented.

Company

About ResMed, Inc.

ResMed Inc. is a global medical technology and digital health company focused on sleep health, respiratory care, and out-of-hospital care. ResMed develops and markets cloud-connected medical devices, including positive airway pressure systems, masks, home ventilators, and related accessories used to diagnose and manage sleep apnea and other chronic respiratory disorders. The company also provides software and connected-care platforms that support home healthcare, post-acute care, and care coordination for providers, patients, and caregivers. Its product portfolio serves hospitals, sleep clinics, home medical equipment suppliers, and long-term care organizations across global markets. ResMed Inc. plays an important role in the healthcare market by combining medical devices with software to improve treatment delivery, patient monitoring, and care management in home and clinical settings.

CEO Mr. Michael J. Farrell BE, MBA, SM · 11,370 employees · United States · https://www.resmed.com